PMID-8329825 – Sermorelin PK and GH Secretion IV vs Intranasal
Evans WS, Borges JL, Vance ML, Kaiser DL, Rogol AD, Furlanetto R, Rivier J, Vale W, Thorner MO. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. J Clin Endocrinol Metab. 1993;76(3):567-573.
Quick Reference
| Property | Value |
|---|---|
| PMID | 8329825 |
| DOI | 10.1210/jcem.76.3.8445013 |
| Year | 1993 |
| Journal | Journal of Clinical Endocrinology & Metabolism |
| Study Type | RCT |
| Evidence Level | II |
| Sample | Healthy adult subjects |
| Peptide(s) Studied | Sermorelin |
Key Findings
- IV sermorelin produced rapid, dose-dependent GH release peaking at 15-30 minutes
- Half-life of sermorelin is approximately 10-20 minutes after IV administration
- Intranasal administration showed lower bioavailability compared to IV/SubQ
- GH response was robust and reproducible across subjects
- Dose-response relationship was well-characterized for IV route
- Intranasal route was explored as a non-invasive alternative but showed variable absorption
Study Design
Controlled pharmacokinetic study comparing IV and intranasal routes of GHRH(1-29)-NH2 administration in healthy subjects. Serial blood sampling for GH and sermorelin levels.
Limitations
- Small sample size (typical of PK studies)
- Healthy young subjects; may not reflect PK in elderly or obese
- Intranasal formulation may have improved since 1993
- Does not assess SubQ route (the most clinically used route)
Clinical Relevance
Establishes the fundamental pharmacokinetic profile of sermorelin: rapid absorption, short half-life (~10-20 min), and prompt GH release. The short half-life explains why bedtime dosing is preferred — the brief stimulation aligns with the natural nocturnal GH surge. The intranasal bioavailability data is relevant for oral/alternative delivery forms including the capsule formulation available from Ageless Peps.
Related
#research #RCT #sermorelin #evidence-level-II